Back to News
Market Impact: 0.15
Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Development
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Pliant Therapeutics appointed David Raben, M.D., as chief medical officer. The leadership addition may support clinical development of the company’s integrin-based therapeutic pipeline, but the announcement contains no trial, financial, or guidance update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PLRX0.35
More News
- Can Trump Oust Powell From the Fed Board? What to Know
- Paramount promised 30 movies a year to win Warner Bros. Losing Miramax if it fails may not scare it
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- AI’s biggest players promise to police themselves at the White House
- Three northern Japan regional banks set to begin merger talks - reports
- Cullinan initiates FDA filing for lung cancer drug zipalertinib